SCHEMBL20332736

SCHEMBL20332736

O=C(Nc1ccccn1)c1ccc(Br)cc1F

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SORT1 Q99523 1/20 0.71
NPC1 O15118 8/20 0.57
RAB9A P51151 8/20 0.57
KMT2A Q03164 4/20 0.57
GAA P10253 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
ALDH1A1 P00352 2/20 0.57
LMNA P02545 1/20 0.57
MEN1 O00255 3/20 0.55
KDM4E B2RXH2 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
GLA P06280 1/20 0.52
POLB P06746 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
CHRNB2 P17787 1/20 0.51
CHRNB4 P30926 1/20 0.51
CHRNA3 P32297 1/20 0.51
CHRNA4 P43681 1/20 0.51
KCNMA1 Q12791 1/20 0.51
TP53 P04637 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27487339 0.86 MEN1 (0.57) SORT1NPC1RAB9AKMT2AGAA
SCHEMBL20610223 0.84 SORT1 (0.68) SORT1NPC1RAB9AKMT2AGAA
SCHEMBL29980979 0.83 SORT1 (1.00) SORT1NPC1RAB9AKMT2AMEN1
SCHEMBL15903084 0.83 SORT1 (1.00) SORT1NPC1RAB9AKMT2AMEN1
SCHEMBL15903086 0.83 SORT1 (0.90) SORT1NPC1RAB9AKMT2AMEN1
SCHEMBL1818730 0.83 SORT1 (0.67) SORT1NPC1RAB9AKMT2AGAA
SCHEMBL30417260 0.83 SORT1 (0.67) SORT1NPC1RAB9AKMT2AGAA
SCHEMBL14636633 0.82 MEN1 (0.69) NPC1RAB9AKMT2AGAASMN1; SMN2
SCHEMBL30362638 0.82 MEN1 (0.69) NPC1RAB9AKMT2AGAASMN1; SMN2
SCHEMBL3846118 0.81 SORT1 (0.73) SORT1NPC1RAB9AKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3858833-B9 AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREOF AND USE THEREOF TRANSTHERA SCIENCES NANJING INC (CN) 2026-03-11 EP disclosed
EP-3858833-B1 AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREOF AND USE THEREOF TRANSTHERA SCIENCES NANJING INC (CN) 2025-10-22 EP disclosed
US-12291534-B2 Aminonorbornane derivative and manufacture method therefor and use thereof TRANSTHERA SCIENCES (NANJING), INC. (CN) 2025-05-06 US disclosed
US-11420975-B2 Substituted imidazo[1,5-a]pyrazines as Bruton's tyrosine kinase inhibitors TRANSTHERA SCIENCES (NANJING), INC. (CN) 2022-08-23 US disclosed
US-20220144843-A1 AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREFOR AND USE THEREOF TRANSTHERA SCIENCES (NANJING), INC. (CN) 2022-05-12 US disclosed
US-20220144843-A1 AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREFOR AND USE THEREOF TRANSTHERA SCIENCES (NANJING), INC. (CN) 2022-05-12 US disclosed
US-20210332057-A1 AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREFOR AND USE THEREOF TRANSTHERA SCIENCES (NANJING), INC. (CN) 2021-10-28 US disclosed
US-20210332057-A1 AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREFOR AND USE THEREOF TRANSTHERA SCIENCES (NANJING), INC. (CN) 2021-10-28 US disclosed
EP-3858833-A1 AMINONORDECANE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Nanjing Transthera Biosciences Co., Ltd. (CN) 2021-08-04 EP disclosed
EP-3858833-A1 AMINONORDECANE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Nanjing Transthera Biosciences Co., Ltd. (CN) 2021-08-04 EP disclosed
WO-2020063012-A1 AMINONORDECANE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 南京亘泰医药技术有限公司 2020-04-02 WO disclosed
WO-2020063012-A1 AMINONORDECANE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 南京亘泰医药技术有限公司 2020-04-02 WO disclosed
WO-2019056466-A1 BRUTON TYROSINE KINASE INHIBITOR 南京亘泰医药技术有限公司 2019-03-28 WO disclosed
WO-2018113085-A1 BRUTON'S TYROSINE KINASE INHIBITOR 南京亘泰医药技术有限公司 2018-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12291534-B2 Aminonorbornane derivative and manufacture method therefor and use thereof BTK, LCK, SYK SORT1 2926/4885NPC1 3453/4885RAB9A 1752/4885
US-11420975-B2 Substituted imidazo[1,5-a]pyrazines as Bruton's tyrosine kinase inhibitors BTK, SYK, LCK SORT1 4598/4885NPC1 3937/4885RAB9A 1111/4885
US-20210332057-A1 AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREFOR AND USE THEREOF BTK, LCK, SYK SORT1 2926/4885NPC1 3453/4885RAB9A 1752/4885
US-20220144843-A1 AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREFOR AND USE THEREOF BTK, LCK, SYK SORT1 2926/4885NPC1 3453/4885RAB9A 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.